| GOSSAMER BIO INC. |
| USA |
| Gesundheit |
| US38341P1021 / A2PCBS |
| 4GB (Frankfurt) / GOSS (NASDAQ) |
| FRA:4GB, ETR:4GB, 4GB:GR, NASDAQ:GOSS |
| - |
| https://www.gossamerbio.c.. |
|
Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in immunology, inflammation, and oncology. It centers its efforts on seralutinib, an investigational inhaled inhibito..
>Volltext.. |
| 74.21 Mio. EUR |
| 130.36 Mio. EUR |
| 41.99 Mio. EUR |
| -140.56 Mio. EUR |
| -147.59 Mio. EUR |
| -0.65 EUR |
| 175.78 Mio. EUR |
| 32.69 Mio. EUR |
| -148.37 Mio. EUR |
| 2.16 |
| -62.75% |
| -165.65% |
| - |
| - |
| - |
| - |
| GOSSAMER BIO |
| 03.04.26 |
|
||||
|